Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avient Corporation (AVNT) vs Gilead Sciences, Inc. (GILD) Price & Performance

Avient CorporationTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Avient Corporation vs Gilead Sciences, Inc. — how do they compare? Avient Corporation trades at $45.51 (market cap $4.19B), while Gilead Sciences, Inc. trades at $135.67 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 39.4× Avient Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.

AVNTGILD
Market Cap
$4.19B$164.99B
Sector
TechnologyHealth
52-Week High
$45.69$155.80
52-Week Low
$27.48$110.56
Enterprise Value
$5.64B$188.06B
Dividend Yield
2.41%2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avient Corporation

Avient Corporation (AVNT) trades at $45.69, up 7.13% with strong technical momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $0.96 exceeding expectations by $0.07. Analyst consensus remains bullish with a $49.00 price target and 60% buy ratings. Recent quarterly dividend of $0.275 per share demonstrates shareholder returns while maintaining operational strength with $299M operating cash flow in 2026.

Outlook remains positive with improved full-year guidance and 20% adjusted EPS growth. Key risks include competitive pressures in chemical sector and potential margin compression. Upside potential exists toward $49-50 resistance zone, supported by strong fundamentals and institutional confidence in management's execution capabilities.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avient Corporation

Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.

Read more on AVNT

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD